HULL'S MAGIC BOX: BUILDING THE CASE FOR CLINICAL TRIALS USING ARGININE METHYLATION INHIBITORS AGAINST GBM

This study evaluates transcriptomic responses in glioblastoma tissue maintained on a microfluidics platform when treated with the arginine methylation inhibitor GSK3368715. The research aims to build evidence supporting clinical trial development for this novel therapeutic approach in GBM treatment.